Gaurav Goel1. 1. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Room 463, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA, goelg@upmc.edu.
Abstract
PURPOSE: Colorectal cancer (CRC) is a major health problem in the USA and worldwide. At the time of initial presentation, approximately 26 % of CRC patients will have stage II disease while another 30 % will present with stage III disease. Although surgical resection plays a critical role in the management of patients who have early-stage disease, it is usually not curative by itself. As a result, adjuvant chemotherapy is generally administered to eradicate clinically occult micrometastatic disease. It is now being increasingly realized that not all patients with stage II and III disease derive significant benefit from adjuvant chemotherapy. Moreover, due to a growing concern for long-term chemotherapy-associated adverse effects, its utility in unselected stage II/III patients is now being questioned. METHODOLOGY AND RESULTS: Significant efforts have been made in recent years to identify potential biomarkers that would help to define the subset of stage II and III colon cancer patients expected to derive significant benefit from adjuvant chemotherapy, especially in those with borderline indications. Oncotype DX Colon Cancer Assay and ColoPrint are gene expression profiling-based recurrence score (RS) assays that have been developed with this intent. The greatest utility of RS assay has been conventionally believed to be for identifying recurrence risk in stage II patients. Recent data now suggests that stage III patients similar to stage II patients, vary in their tumor recurrence risk and that there might be a role for a more selective approach in treating these patients, based on the results of RS assays. CONCLUSION: In such an evolving landscape, this article aims to review the current role of gene expression signatures such as Oncotype DX and ColoPrint in the management of early-stage colon cancer.
PURPOSE:Colorectal cancer (CRC) is a major health problem in the USA and worldwide. At the time of initial presentation, approximately 26 % of CRCpatients will have stage II disease while another 30 % will present with stage III disease. Although surgical resection plays a critical role in the management of patients who have early-stage disease, it is usually not curative by itself. As a result, adjuvant chemotherapy is generally administered to eradicate clinically occult micrometastatic disease. It is now being increasingly realized that not all patients with stage II and III disease derive significant benefit from adjuvant chemotherapy. Moreover, due to a growing concern for long-term chemotherapy-associated adverse effects, its utility in unselected stage II/III patients is now being questioned. METHODOLOGY AND RESULTS: Significant efforts have been made in recent years to identify potential biomarkers that would help to define the subset of stage II and III colon cancerpatients expected to derive significant benefit from adjuvant chemotherapy, especially in those with borderline indications. Oncotype DX Colon Cancer Assay and ColoPrint are gene expression profiling-based recurrence score (RS) assays that have been developed with this intent. The greatest utility of RS assay has been conventionally believed to be for identifying recurrence risk in stage II patients. Recent data now suggests that stage III patients similar to stage II patients, vary in their tumor recurrence risk and that there might be a role for a more selective approach in treating these patients, based on the results of RS assays. CONCLUSION: In such an evolving landscape, this article aims to review the current role of gene expression signatures such as Oncotype DX and ColoPrint in the management of early-stage colon cancer.
Authors: Richard G Gray; Philip Quirke; Kelly Handley; Margarita Lopatin; Laura Magill; Frederick L Baehner; Claire Beaumont; Kim M Clark-Langone; Carl N Yoshizawa; Mark Lee; Drew Watson; Steven Shak; David J Kerr Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Ramon Salazar; Paul Roepman; Gabriel Capella; Victor Moreno; Iris Simon; Christa Dreezen; Adriana Lopez-Doriga; Cristina Santos; Corrie Marijnen; Johan Westerga; Sjoerd Bruin; David Kerr; Peter Kuppen; Cornelis van de Velde; Hans Morreau; Loes Van Velthuysen; Annuska M Glas; Laura J Van't Veer; Rob Tollenaar Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Shuji Ogino; Robert D Odze; Takako Kawasaki; Mohan Brahmandam; Gregory J Kirkner; Peter W Laird; Massimo Loda; Charles S Fuchs Journal: Am J Surg Pathol Date: 2006-09 Impact factor: 6.394
Authors: S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein Journal: Cancer Res Date: 1990-12-01 Impact factor: 12.701
Authors: J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Greg Yothers; Michael J O'Connell; Mark Lee; Margarita Lopatin; Kim M Clark-Langone; Carl Millward; Soonmyung Paik; Saima Sharif; Steven Shak; Norman Wolmark Journal: J Clin Oncol Date: 2013-11-12 Impact factor: 44.544
Authors: Paul Lochhead; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Mai Yamauchi; Reiko Nishihara; Zhi Rong Qian; Teppei Morikawa; Jeanne Shen; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino Journal: J Natl Cancer Inst Date: 2013-07-22 Impact factor: 13.506
Authors: Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240